Vanguard Group Inc. lessened its position in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX – Free Report) by 1.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,869,079 shares of the biotechnology company’s stock after selling 58,518 shares during the quarter. Vanguard Group Inc. owned about 0.07% of Aldeyra Therapeutics worth $12,652,000 as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new position in shares of Aldeyra Therapeutics in the 4th quarter worth approximately $39,000. NorthRock Partners LLC purchased a new position in shares of Aldeyra Therapeutics in the 4th quarter worth approximately $42,000. Kingswood Wealth Advisors LLC purchased a new position in shares of Aldeyra Therapeutics in the 1st quarter worth approximately $49,000. BNP Paribas Financial Markets boosted its holdings in shares of Aldeyra Therapeutics by 23.4% in the 1st quarter. BNP Paribas Financial Markets now owns 25,278 shares of the biotechnology company’s stock worth $83,000 after purchasing an additional 4,797 shares during the period. Finally, Denali Advisors LLC purchased a new position in shares of Aldeyra Therapeutics in the 1st quarter worth approximately $155,000. Hedge funds and other institutional investors own 59.71% of the company’s stock.
Aldeyra Therapeutics Stock Down 0.8 %
ALDX opened at $4.71 on Wednesday. The business has a fifty day moving average of $3.73 and a 200 day moving average of $3.69. Aldeyra Therapeutics, Inc has a 52-week low of $1.42 and a 52-week high of $7.88. The stock has a market cap of $279.84 million, a P/E ratio of -9.25 and a beta of 1.45.
Analyst Ratings Changes
Check Out Our Latest Analysis on Aldeyra Therapeutics
About Aldeyra Therapeutics
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-?B, inflammasomes, and Scavenger Receptor A.
Further Reading
- Five stocks we like better than Aldeyra Therapeutics
- The Risks of Owning Bonds
- Buy On Holdings Stock Before the Market Catches Its Second Wind?
- 5 discounted opportunities for dividend growth investors
- 3 High-Potential Stocks That Could Turn Into Multi-Baggers
- What Are the U.K. Market Holidays? How to Invest and Trade
- CEO Swap: Starbucks Surges 22% on Hiring New CEO From Chipotle
Want to see what other hedge funds are holding ALDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aldeyra Therapeutics, Inc (NASDAQ:ALDX – Free Report).
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.